See more : T.T. Limited (TTL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Akero Therapeutics, Inc. (AKRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Akero Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- American Express Company (AEC1.DE) Income Statement Analysis – Financial Results
- CUC Inc. (9158.T) Income Statement Analysis – Financial Results
- Rubellite Energy Inc. (RBY.TO) Income Statement Analysis – Financial Results
- Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG (EFF.DE) Income Statement Analysis – Financial Results
- Tectonic Metals Inc. (TETOF) Income Statement Analysis – Financial Results
Akero Therapeutics, Inc. (AKRO)
About Akero Therapeutics, Inc.
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 29.00K | 260.00K | 244.00K | 213.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -29.00K | -260.00K | -244.00K | -213.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 141.80M | 85.28M | 81.76M | 64.92M | 37.05M | 11.88M | 3.49M |
| General & Administrative | 31.07M | 29.87M | 19.13M | 15.24M | 8.61M | 1.90M | 1.18M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -98.00K |
| SG&A | 31.07M | 29.87M | 19.13M | 15.24M | 8.61M | 1.90M | 1.08M |
| Other Expenses | 0.00 | 3.86M | 109.00K | 947.00K | 1.90M | -67.94M | 0.00 |
| Operating Expenses | 172.87M | 115.16M | 100.89M | 80.15M | 45.65M | 13.78M | 4.56M |
| Cost & Expenses | 172.87M | 115.16M | 100.89M | 80.15M | 45.65M | 13.78M | 4.56M |
| Interest Income | 24.21M | 3.86M | 109.00K | 947.00K | 1.90M | 0.00 | 0.00 |
| Interest Expense | 3.10M | 739.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 29.00K | 260.00K | 244.00K | 213.00K | -104.00K | 13.78M | 4.98M |
| EBITDA | -148.63M | -111.03M | -100.53M | -78.99M | -45.65M | -68.46M | -232.36K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -172.87M | -115.16M | -100.89M | -80.15M | -45.65M | -13.78M | -4.56M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 21.11M | 3.12M | 109.00K | 947.00K | 1.90M | -67.94M | 0.00 |
| Income Before Tax | -151.76M | -112.03M | -100.78M | -79.21M | -43.76M | -81.71M | -4.56M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.12M | -41.00K | -17.00K | 24.00K | -68.10M | -4.98M |
| Net Income | -151.76M | -108.91M | -100.74M | -79.19M | -43.76M | -81.71M | -4.56M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.89 | -2.79 | -2.89 | -2.52 | -2.90 | -3.85 | -0.16 |
| EPS Diluted | -2.89 | -2.79 | -2.89 | -2.52 | -2.90 | -3.85 | -0.16 |
| Weighted Avg Shares Out | 52.57M | 38.98M | 34.83M | 31.46M | 15.07M | 21.22M | 28.56M |
| Weighted Avg Shares Out (Dil) | 52.57M | 38.98M | 34.83M | 31.46M | 15.07M | 21.22M | 28.56M |
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three orthogonal measures: (1) ≥1-stage fibrosis improvement by NASH-CRN stage (conventional histopathology), (2) 30% reduction...
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside...
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
— First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH —
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced an upcoming oral presentation and...
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm
NEW YORK , Sept. 30, 2024 /PRNewswire/ -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO) Shareholders should email [email protected]; please contact only if shares acquired before September...
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside...
Akero Therapeutics: Good Candidate For The MASH Basket
Akero Therapeutics' Efruxifermin (EFX) showed strong results in pre-cirrhotic MASH, but failed in cirrhotic MASH, impacting stock performance. The MASH market is highly competitive with many pipeline drugs and one approved drug, resmetirom, creating significant risk for AKRO. Akero has...
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
Outcomes is the third study in the Phase 3 SYNCHRONY clinical trial program SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high...
Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Morgan...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)
NEW YORK , Aug. 23, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Akero Therapeutics, Inc. (NASDAQ: AKRO) on behalf of the company's shareholders. The investigation seeks to determine whether Akero's directors breached their fiduciary duties...
Source: https://incomestatements.info
Category: Stock Reports